Home » Authors » Jennifer Boggs

Jennifer Boggs

Articles

ARTICLES

After First Product Approval, BioMimetic Seeks $50M IPO

Feb. 13, 2006

By Jennifer Boggs

Inflabloc Adds Cancer Drugs Through Merger, Raises $6M

Feb. 10, 2006

By Jennifer Boggs

Inflabloc Adds Cancer Drugs Through Merger, Raises $6M

Feb. 10, 2006

By Jennifer Boggs

Immtech Prices $16M Public Offering; EpiCept Adds $11M

Feb. 9, 2006

By Jennifer Boggs

Immtech Prices $16M Public Offering; EpiCept Adds $11M

Feb. 9, 2006

By Jennifer Boggs

ARYx Series E Gets $30M To Fund Proof Of Concept

Feb. 8, 2006

By Jennifer Boggs

ARYx Series E Gets $30M To Fund Proof Of Concept

Feb. 8, 2006

By Jennifer Boggs

QuatRx Files $86M IPO To Push Clinical Development

Feb. 7, 2006

By Jennifer Boggs

A month after starting its first Phase III trial, QuatRx Pharmaceuticals Co. filed for its initial public offering, hoping to raise $86.25 million. (BioWorld Today)

QuatRx Files $86M IPO To Push Clinical Development

Feb. 7, 2006

By Jennifer Boggs

A month after starting its first Phase III trial, QuatRx Pharmaceuticals Co. filed for its initial public offering, hoping to raise $86.25 million. (BioWorld Today)

EntreMed Boosting Cancer Work With $30M Placement

Feb. 6, 2006

By Jennifer Boggs

View All Articles by Jennifer Boggs

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 16, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...